Ask the Experts:Optimizing Immunotherapy for Cancer Patients

PROGRAM DESCRIPTION This educational activity will focus on the role of PD-1 and PD-L1 inhibitors and their role in treating patients with cancer and clinical evidence and cost of individualized ...

PROGRAM DESCRIPTION
This educational activity will focus on the role of PD-1 and PD-L1 inhibitors and their role in treating patients with cancer and clinical evidence and cost of individualized and flat dosing of PD-1 and PD-L1 inhibitors. Clinical evidence supporting the use of PD-1 and PD-L1 inhibitors in cancer patients with comorbidities related to organ dysfunction and altered immunity will also be discussed.The content for this activity is based on questions and comments from participants at a recent educational symposium on this topic.

EDUCATIONAL OBJECTIVES
At the conclusion of this application-based educational activity, participants should be able to:Review the pharmacology and pharmacokinetics of PD-1 and PD-L1 inhibitors.Compare and contrast the clinical evidence and cost of individualized and flat dosing of PD-1 and PD- L1 inhibitors.Discuss the evidence supporting the use of PD-1 and PD-L1 inhibitors in cancer patients with comorbidities related to organ dysfunction and altered immunity.

---

Write the first review

Resource tags